Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
IPCA Laboratories Ltd. clinical trials
The registry lists 30 studies whose lead sponsor is IPCA Laboratories Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 24, 2013.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to IPCA Laboratories Ltd..
- IPCA Laboratories Ltd.30 studiesSame company
Something wrong?
Focus areas
Conditions IPCA Laboratories Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 30 of 30.
- Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mgCompletedNCT01884857Phase 1
- Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting ConditionsCompletedNCT01884896Phase 1
- Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed ConditionsCompletedNCT01884909Phase 1
- Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed ConditionCompletedNCT01831674Phase 1
- Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting ConditionsCompletedNCT01831700Phase 1
- Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed ConditionCompletedNCT01831687Phase 1
- Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting ConditionCompletedNCT01831661Phase 1
- Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fasting ConditionCompletedNCT01827865Phase 1
- Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed ConditionsCompletedNCT01827878Phase 1
- Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed ConditionCompletedNCT01749228Phase 1
- Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting ConditionCompletedNCT01746719Phase 1
- Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed ConditionCompletedNCT01744873Phase 1
- Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting ConditionCompletedNCT01741623Phase 1
- Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed ConditionCompletedNCT01735344Phase 1
- Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed ConditionCompletedNCT01567501Phase 1
- Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fasting ConditionCompletedNCT01557439Phase 1
- Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting ConditionCompletedNCT01735318Phase 1
- Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting ConditionCompletedNCT01735370Phase 1
- Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed ConditionCompletedNCT01735383Phase 1
- Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting ConditionCompletedNCT01722201Phase 1
- Bioequivalence Study of Indomethacin Extended-Release Capsules 75 mg Under Fed ConditionCompletedNCT01722110Phase 1
- Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg Under Fed ConditionCompletedNCT01603186Phase 1
- Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting ConditionCompletedNCT01577914Phase 1
- Bioequivalence Study of Risperidone Tablet 1 mg Under Fed ConditionCompletedNCT01618760Phase 1
- Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed ConditionCompletedNCT01618825Phase 1
- Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting ConditionCompletedNCT01618799Phase 1
- Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg Under Fasting ConditionCompletedNCT01603173Phase 1
- Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting ConditionCompletedNCT01603134Phase 1
- Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed ConditionCompletedNCT01578265Phase 1
- Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting ConditionCompletedNCT01578252Phase 1